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DEFINITIONS
The classical definition of a stem cell requires two criteria to be fulfilled 
1. The ability of self-renewal. 
2. The ability to differentiate into specialized cell types.  
This means that a stem cell can undergo mitotic cell division to two identical daughter 
cells with identical properties as the mother cell, or to one cell resembling its mother and 
to another more differentiated cell. Alternatively, both daughter cells can be more 
differentiated. The more mature descendants of the mother cell can further divide to give 
rise to a progeny of mature cells with more specialized properties. 
Hierarchy of potency 
Stem cells can be classified according to their potency for differentiation: 
Totipotent stem cells 
The fertilized oocyte (the zygote) and the descendants of the first two cell divisions are 
totipotent stem cells. This means that they are able to form both the embryo and the 
placenta. 
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Pluripotent stem cells 
During embryogenesis, the totipotent stem cells form a hollow ball of cells (the 
blastocyst) which gives rise to the placenta, and the inner cell mass which contains the 
embryonic stem cells (ESC). ESC are pluripotent, i.e. they are able to differentiate to 
cells of all three germ layers, the endoderm, the mesoderm and the ectoderm, but not the 
placenta. 
Multipotent stem cells 
The traditional definition of multipotent stem cells is the capability of differentiation to a 
limited range of cell lineages. The hematopoietic stem cells (HSC) are multipotent. 
Unipotential stem cells 
These cells are capable of differentiation to one specific cell type. One example is the 
myoblast. These cells are often referred to as progenitor cells, e.g. endothelial progenitor 
cells (EPC). 
Embryonic versus adult stem cells 
As stated above, the ESC comprise the inner cell mass of the blastocyst. Adult stem cells 
are stem cells found in developed tissues and can be found both in children and adults. 
Adult stem cells are often referred to as somatic stem cells. 
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MOTIVATION
Cardiovascular disease is a major global health problem, accounting for approximately 17 
million deaths worldwide each year, and the majority of these deaths are caused by 
ischemic heart disease1. Modern reperfusion strategies with fibrinolyis or percutaneous 
intervention (PCI), and medical treatment with antiplatelet agents, beta-blockers, ACE-
inibitors and/or angiotensin receptor blockers and statins have improved prognosis for 
patients with myocardial infarction2. After acute occlusion of a coronary artery, 
myocardial infarction can be aborted when reperfusion is obtained within 30 minutes3.
However, since the majority of these patients will receive reperfusion later, most will 
develop myocardial infarction with necrotic myocardial cell death through oncosis and to 
a lesser degree apoptosis4. Especially patients with large, transmural infarctions are at 
risk of remodeling, characterized by a general change in ventricular size, geometry and 
function, and the development of congestive heart failure (CHF)5, 6. Patients diagnosed 
with CHF have a dismal prognosis with an expected 1-year mortality of 20%7. None 
existing therapy can provide myocardial repair, and new treatment options with potential 
for myocardial regeneration are needed. 
MYOCARDIAL REGENERATION 
The long-lasting paradigm that the human heart cannot regenerate has recently been 
challenged by several observations. Adult mature cardiomyocytes are terminally 
differentiated and have either no or limited regenerative capacity since they are unable to 
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reenter the cell cycle8. However, a low-grade continuous cardiomyocyte death by 
apoptosis seem to be a normal phenomenon in the human heart9, and even conservative 
estimates of normal cell death indicate that the entire human heart would disappear within 
a few decades if there was no regeneration10. Currently, there is growing evidence that 
there is a continuous low-rate turn-over of cardiomyocytes throughout life11. Several stem 
cell populations have been identified within the mammalian (including the human) 
heart12, and the numbers of replicating cells within the myocardium are increased in 
pathological conditions like ischemic and idiopathic cardiomyopathy13, pressure 
overload14 and after myocardial infarction15. Cardiac stem cells may be remnants from 
embryonic development maintained in specific niches within the heart. However, several 
observations indicate that the bone marrow is involved in cardiac repair, and that cardiac 
stem cells may derive from the bone marrow16, 17.
Bone marrow cells for myocardial regeneration 
At the turn of the millennium, the regenerative capacity of the bone marrow was shown 
to be greater than previously thought. HSC are the best characterized adult stem cells. 
They are multipotent, and have the ability to differentiate to several types of bone marrow 
and blood cells. HSC transplantations have been used for more than 50 years to 
repopulate the bone marrow of ablated recipientes18. However, new data indicated that 
HSC and other cells derived from bone marrow (BMC) possessed a property of 
developmental plasticity. This means an ability to differentiate across boundaries of 
lineage, tissue or germ layer and acquire an unexpected phenotype in a process called 
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transdifferentiation.  According to the environment where the cells were placed, BMC 
were shown to transdifferentiate into cells of such different organs as brain19, liver20 and 
skeletal muscle21. In 2001, BMC were found to transdifferentiate to endothelial cells, 
smooth muscle cells and cardiomyocytes, and to regenerate the myocardium in 
experimental models of acute myocardial infarction (AMI) in mice22, 23.
The bone marrow contains a hierarchy of stem cell populations with varying potential for 
differentiation. The multipotent adult progenitor cells (MAPC) are primitive cells with 
the potential for in-vitro differentiation to cell types of all three germ layers after being 
injected into the early blastocyst24. These cells may be the precursors of the 
hemangioblast which typically express the surface markers CD34 and CD13325, and the 
mesenchymal stem cells / multipotent mesenchymal stromal cells (MSC). MSC are 
primarily characterized by their ability to adhere to plastic in culture and their multipotent 
differentiation capacity in vitro26. The hemangioblast is the precursor of the HSC, which 
also typically express CD34 and CD13327, and to the EPC. Characterisation of EPC is not 
uniform, but some features include expression of CD34 and the receptor for vascular 
endothelial growth factor, VEGFR2(KDR), the lack of markers seen on fully 
differentiated endothelial cells, and the potential to form mature endothelial cells in 
culture28. Circulating cells with similar properties are often referred to as circulating 
progenitor cells (CPC). In addition a stem cell population of side population (SP) cells, 
characterized by their ability to expel the Hoechst dye 33342 has been identified. SP-cells 
may have the ability to reconstitute the entire bone marrow after single cell grafting29. All 
these bone marrow cell populations are mononucleated and they are scarce. Multipotent 
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HSC constitute approximately 0.01% of all blood cells within the bone marrow30, and the 
amount of MSC is probably 10-fold less31.
Studies in patients after sex-mismatched bone marrow or cardiac transplantation support 
that BMC are involved in cardiac repair. In such studies, the sex-chromosomes can be 
used to identify cells of non-cardiac origin. In male recipients of female hearts, large 
numbers of XY-chromosome positive endothelial, smooth muscle cells and 
cardiomyocytes have been found in the transplanted hearts32. Similarly, in female 
recipients of male hearts, XX-chromosome positive cardiomyocytes were identified33.
The origin of these cells is not clarified, and it has been postulated that intrinsic cardiac 
stem cells from remniscent atrial tissue may have populated the transplanted heart. 
However, XY-chromosome positive cardiomyocytes34 and smooth muscle cells35 have 
been identified in female recipients of male bone marrow, suggesting that circulating 
BMC have homed to the heart and transdifferentiated. Thus, regeneration of the heart by 
BMC may be a naturally occurring phenomenon that handles the need for the continuous, 
low-grade turn-over of cardiac cells. However, this mechanism is obviously insufficient 
in the setting of acute large cell loss, since myocardial infarction heals with scar 
formation36. Therefore, attempts to enforce BMC mediated cardiac repair by direct 
transplantation of cells to the heart were tempting, and clinical studies were started 
promptly after the publication of the initial studies in rodents22, 23, 37.
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In 2002, Strauer et al described a technique for intracoronary injection of BMC in 
patients with AMI after acute reperfusion with PCI38. The same technique was used for 
injection of either BMC or CPC in the TOPCARE-AMI study39. These studies indicated 
that the treatment was feasible and safe, and the results indicated reduced infarct size and 
improved left ventricle (LV) function and perfusion after BMC treatment. However, 
interpretation of results was hampered by the unrandomized study designs and small 
patient groups. 
THE AUTOLOGOUS STEM CELL TRANSPLANTATION IN ACUTE 
MYOCARDIAL INFARCTION (ASTAMI) STUDY
On this background, during autumn 2002, we started to explore the possibility for a 
Norwegian, randomized clinical trial with intracoronary injection of autologous 
mononuclear BMC (mBMC) in patients with AMI. It was soon realized that several 
departments at several institutions needed to be involved to conduct such a trial. A 
steering committee with members from Rikshospitalet University Hospital (RUH), 
Ullevål University Hospital (UUH) and the University of Oslo (UiO) was founded, and 
the protocol for the ASTAMI study was prepared. Drs Knut Rasmussen, Lars Wallentin 
and Rune Wiseth agreed to participate in a data and safety monitoring board. Dr Svein 
Solheim was engaged as research fellow at UUH, and dr Ketil Lunde at RUH. The 
protocol was approved by the regional ethics committee on June 3, 2003. The use of 
mBMC in the ASTAMI study was subject to the Medicines for Human Use (Clinical 
Trials) regulations (CPMP/ICH/291/95) on Good Clinical Practice (GCP), and needed 
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approval by The Norwegian Medicines Agency (NoMA). A revised protocol was 
approved by NoMa Agency on September 3, 2003. The first patient was included in the 
study on September 11, 2003. Application to The Data Inspectorate was sent on 
September 9, 2003 and after approval on January 28, 2004, collected data could be 
entered into the electronic database. 
Steering committee
Kolbjørn Forfang (Chair) Department of Cardiology, RUH 
Harald Arnesen  Department of Cardiology, UUH 
Torstein Egeland  Institute of Immunology, RUH 
Knut Endresen  Department of Cardiology, RUH 
Arnfinn Ilebekk  Institute for Experimental Medical Research, UiO  
Arild Mangschau  Department of Cardiology, UUH 
Svend Aakhus   Department of Cardiology, RUH 
Aims of the study
We wanted to investigate whether intracoronary injection of autologous mBMC in 
patients with AMI resulted in clinically important effects on: 
1) LV function. The primary aim was to examine whether mBMC treatment resulted 
 in at least 5% improvement of the change in left ventricular ejection fraction 
 (LVEF) from baseline to 6 months follow-up compared to controls. 
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2) Exercise capacity assessed as peak VO2 and quality of life assessed by the Short 
 Form 36 (SF-36) health survey (secondary aim). 
3) Infarct size (additional aim).  
Furthermore, to examine whether any such changes were correlated to the number of 
mBMC or subpopulations injected. Finally, to assess the safety of this treatment during 
12 months follow-up. In the protocol, an additional aim was to assess the effects of 
mBMC treatment on biochemical signaling responses. The latter issue is not a part of the 
present thesis.   
Methods
Design
The ASTAMI study was an open-labeled, randomized clinical trial. A sham procedure 
with bone marrow aspiration and intracoronary injection of placebo medium in control 
patients was considered unethical, since this would expose these patients to the risks of 
the procedures without the possibility for a beneficial effect of cell injections. Major parts 
of the protocol are presented in paper I, and in the appendix of paper II. Here, the 
protocol is presented in short, and some issues are further elaborated. All patients with 
ST-segment elevation acute myocardial infarction (STEMI) admitted for acute PCI at 
RUH in the period September 3, 2003 to May 4, 2005, and at UUH between mid 
September, 2003 and May 4, 2005 were screened for inclusion in the study, and eligible 
patients were invited to participate.  
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Inclusion criteria: All criteria must be fulfilled. 
x Age between 40 and 75 years. 
x Acute anterior wall myocardial infarction with a history >3 hours and <12 hours. 
x ST elevation infarction (WHO ECG criteria). 
x Angiographic criteria: Occlusion (TIMI flow 0 – 1) of the left anterior descending 
(LAD) coronary artery proximal to the second diagonal branch.  
x Successful primary or rescue PCI (TIMI flow 2 or better). 
x Echocardiographic criteria: Evidence for anterior wall infarction as judged by 
hypo- or akinesia in more than 2 adjacent anterior wall segments. 
x Enzymatic criteria: CKMBmass >3 times upper normal value. 
Exclusion criteria: 
x Previous myocardial infarction with established significant Q waves on ECG.
x Cardiogenic shock. 
x Hemodynamic instability necessitating intraaortic balloon pump treatment. 
x Permanent pacemaker or other contraindications to magnetic resonance imaging 
(MRI).
x Stroke with significant sequela. 
x Short life expectancy due to extra cardiac reason, e.g. chronic obstructive lung 
disease, disseminated malignant disease, or other reason. 
x Uncontrolled endocrinological disturbance. 
x Anamnestic indications for significant mental disorder, including dementia.  
x Established HIV or hepatitis B infection. 
x Any condition which interferes with patients possibility to comply with the 
protocol.
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Protocol change 
Since there was widespread use of primary or facilitated thrombolysis before transfer for 
acute PCI, many patients had more than TIMI I flow in the LAD before PCI. Because the 
logistics for transfer of AMI patients for acute PCI in Norway is effective, many patients 
received PCI less than 3 hours after symptom onset. Nevertheless, many of these patients 
developed extensive infarctions. Therefore, on October 8, 2003, inclusion criteria #4 was 
changed to: Acute anterior wall myocardial infarction with a history >2 hours and < 12 
hours. On January 27, 2004, inclusion criteria #3 was changed to: Angiographic criteria: 
Significant stenosis proximal to the second diagonal branch
After obtaining written informed consent, patients were randomized 1:1 to either the 
treatment group or the control group by a permuted block randomization which was 
stratified according to study center. The block size was 4. Center for Clinical Research at 
UUH provided consecutively numbered, sealed envelopes. 
In total, 1608 patients were screened for inclusion in the study (Figure 2, paper II). 
Bone marrow aspiration and processing of mononuclear bone marrow cells
The protocol for bone marrow aspiration and preparation was based on standardized 
methods used in the field of hematology40. Approximately 50 ml bone marrow was 
considered the maximum volume of bone marrow feasible for aspiration in local 
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anaesthesia, and a similar volume had been used in the previous trials which suggested an 
effect of intracoronary administration of mBMC38, 39. The bone marrow underwent 
density gradient centrifugation on Ficoll-isopaque (Lymphoprep™, Axis-Shield, Oslo, 
Norway) for isolation of mononuclear cells, and after washing, cells were stored in 0.9% 
NaCl with 20% autologous heparin plasma. All cell processing were performed at the Ex-
vivo cell laboratory at the Institute for Immunology at RUH under Good Manufacturing 
Practice (GMP) regulations. In the cell processing protocol sent to the NoMA, it was 
planned to use the cell culture medium RPMI-1640 (Gibco®, Invitrogen Ltd, Paisley, 
UK) for cell storage. Due to insufficient safety data for human use, RPMI-1640 was not 
approved by the NoMA, and therefore replaced with autologous heparin-plasma in the 
final protocol. NoMA found documentation for Lymphoprep™  satisfactory. 
Protocol change 
In the original protocol, it was allowed  to perform the intracoronary cell injections either 
on the same day as bone marrow aspiration and preparation of mBMC, or to store the 
prepared mBMC overnight before injections. All aspirates were tested for bacterial 
contamination. In one mBMC sample from a patient with aspiration, preparation and 
intracoronary injection on the same day, contamination with staphylococci was 
discovered the next day, and the protocol was changed. After November 3, 2005, cells 
could only be delivered from the Institute of Immunology after preliminary testing of 
overnight bacteriological specimens were found negative.  
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Intracoronary injection of mBMC 
A PCI stop-flow technique first described by Strauer et al38 was used for intracoronary 
injection of mBMC either the same day, or the day following bone marrow aspiration. 
After intubation of the left coronary ostium with a 6 French catheter, a 0.5 mm oversized 
over-the-wire balloon catheter was advanced to the proximal part of the culprit lesion 
stent in the LAD. One third of the cell solution was injected during 90 s balloon inflation 
and no-flow, followed by 5 min reperfusion. The procedure was repeated twice.
Assessment of LV function 
We used ECG-gated single-photon-emission computed tomography (SPECT), 
echocardiography and MRI to obtain LV end-diastolic (LVEDV) and end-systolic 
(LVESV) volumes. By each imaging modality, LVEF was calculated as: 
(LVEDV – LVESV) / LVEDV x 100%. 
Different imaging modalities have different strengths and weaknesses2, and the rationale 
for the use of three imaging modalities was both the need for a comprehensive evaluation 
of all aspects of LV function, and the possibility for methodological comparisons. The 
latter issue is not a part of this thesis. 
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SPECT
SPECT was the prespecified primary imaging modality for assessment of LV function, 
and the change in LVEF obtained by SPECT was the primary end point of the study. 
SPECT was chosen for several reasons. Data for variability of LVEF with scintigraphic 
techniques had previously been obtained in 93 patients with myocardial infarction at 
UUH. The estimated standard deviation (SD) for LVEF was 8.3%, and was used for 
calculating study sample size. Furthermore, SPECT recordings could be obtained at 
baseline at both centers, and SPECT is probably the best validated method for assessment 
of infarct size41. SPECT recordings were obtained at baseline (4.0±1.4 days) and repeated 
after 6 months. 
Echocardiography
2-dimensional echocardiograpy was used for supplementary information on global LV 
function. Multiple parasternal and apical imaging planes were used to obtain the wall 
motion score index (WMSI) for assessment of regional LV function. Echocardiograms 
were obtained at baseline (4.5±1.1 days), and repeated after 3, 6 and 12 months, allowing 
the assessment of serial changes in LV function. Results obtained by Doppler 
echocardiography, tissue velocity imaging and dobutamine stress-echocardiograpy are 
not a part of this thesis. 
MRI
MRI was used for supplementary information on LV global function and infarct size with 
gadolinium late enhancement contrast imaging. For two reasons, baseline recordings for 
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MRI were obtained 2-3 weeks after the acute infarction. Due to tissue edema, infarct size 
is overestimated when MRI is obtained in the acute phase of a myocardial infarction42.
Furthermore, the capacity for MRI is limited, and it was considered impossible to 
perform all recordings in the acute phase. Since all MRI was obtained at RUH, the 
transfer of patients from UUH in the acute phase would also have caused logistic 
problems. MRI was repeated at 6 months. 
A detailed description of cell processing and transfer, and cardiac imaging is provided in 
the appendix of paper II, which was published with the full text of the paper at 
www.nejm.org43.
Repeatability
Re-read repeatability of LVEF was assessed several months after the original analyses in 
a random subset of 25 patients` 6 months recordings. These patients were chosen for 
repeatability studies since they also participated in a study for assessment of LV volumes 
with the use of 3D-echocardiography where they were included on a consecutive basis44.
SPECT
Two technicians who were unaware of treatment allocation analyzed all SPECT 
recordings en-bloc, and the same technician analyzed baseline and 6 month recordings for 
the same patient. Technician A analyzed 53 pairs of recordings, and technician B 47. In 
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the repeatability study, technician A re-read 8 recordings, and technician B 17 recordings. 
The Bland-Altman plot is presented in Figure 1.
Figure 1 
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Echocardiography
Echocardiograms were obtained by several investigators, blinded and then analyzed en-
bloc by a single investigator (KL). The Bland-Altman plot for intra-observer variability is 
presented in Figure 2. 
Figure 2 
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MRI
MRI was analyzed on a consecutive basis by two investigators who were unaware of 
treatment allocation. Recordings obtained at 6 months were not necessarily analyzed by 
the investigator who performed the analysis at 2-3 weeks. Therefore, interobserver 
variability was considered of major importance. Two methods for obtaining MRI was 
used, turbo fast low-angle shot (FLASH) and true fast imaging with steady-state free 
procession (trueFISP). The same technique was used for the same patient at 2-3 weeks 
and at 6 months. Paired data were obtained for 63 patients with FLASH and 24 with 
trueFISP. To obtain repeatability data for 25 patients by each method, the MRI 
investigators included further patients over the 25 patients in the SPECT and 
echocardiography repeatability study on an arbitrary basis. Bland-Altman plots of inter-
observer variability by the two methods are shown in Figure 3. 
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Figure 3 
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Coronary angiography 
All patients were treated with PCI with stenting of culprit lesion in the proximal or mid 
portion of the LAD. Stent type was chosen according to the preference of the PCI 
operator. Complete angiograms were obtained before stenting, and repeated after 6 
months, and quantitative coronary angiography (QCA) on the LAD were performed at 
both occations with the use of CMS™ Medis software (Sectra Imtec AB, Linkøbing, 
Sweden). All angiograms were analyzed en-bloc by a single investigator (AR) who was 
unaware of treatment allocation. 
Exercise testing and quality of life 
Patients performed maximal, symptom-limited bicycle spiroergometry and answered the 
Norwegian version 1.2 of the SF-36 health survey 2-3 weeks and 6 months after the acute 
event (see methods in paper III for a detailed description). 
GCP inspection 
On September 27, 2004, NoMA notified GCP-inspection of the ASTAMI study. The 
inspection was founded on § 3 of Act no. 132 of December 4, 1992 relating to Medicines 
etc. (Medicines Act), the Regulation relating to clinical trials on medical products for 
human use of  June 18, 1999 and/or September 24, 2003, and the Personal Data Act of 
February 21, 2003. Three GCP-inspectors from the NoMA carried out full-time 
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inspection at UUH on November 9-10, 2004 and at RUH on November 11-12, 2004. The 
aim of the inspection was to assess if the systems for maintaining the study was taken 
care of. Raw-data for 10 patients at each center were checked. All patients were found to 
be eligible according to the inclusion and exclusion criteria, and data in the case report 
formulas (CRF) did not differ from the raw-data. 
Plan for amendment of discrepancies was sent from UUS on March 18, 2005 and from 
RUH on April 8, 2005. The NoMA approved the plan and closed the GCP inspection for 
UUH on March 30, 2005, and for RUH on April 18, 2005.  
Monitoring of data quality 
Ragnhild Kleve at the Department of Preventive Cardiology at UUH monitored data 
quality, i.e. the transition of raw-data via paper version CRF to the electronic database. 
Data for LV volumes and LVEF by all methods were controlled in all patients. All data in 
the CRF were controlled for a random subset of 10 patients at RUH and 8 at UUH. There 
were no discrepancies for the LV function data, and data quality was generally high. 
Sample size and statistics 
A clinically important treatment effect of mBMC treatment was estimated to be a 
difference between groups of 5% points for the change in LVEF from baseline to 6 
months. With a significance level (Type I error or Į) at 5%, a Type II error or ȕ at 20% 
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which gives a power (1-ȕ) of 80%, and an estimated SD of LVEF measurement of 8.3% 
by scintigraphic techniques, it was calculated that 45 patients were needed in each group. 
To allow for some drop-outs, it was decided to include a total of 100 patients. All data 
were analyzed and presented according to the intention-to-treat principle. The statistical 
methods used are presented specifically in each paper.  
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SUMMARY OF RESULTS
Paper I 
This paper presents the design of the ASTAMI study. The paper also includes a study on 
safety aspects of bone marrow aspiration and intracoronary mBMC injections. Data 
obtained by August 2004 were included. At that time, 1004 patients were screened for 
inclusion and 49 were included in the study, 24 were randomized to the mBMC group 
and 25 to the control group. There were no complications related to the bone marrow 
aspiration procedure, but contamination with coagulase-negative staphylococci was 
discovered in one aspirate before intracoronary injection, and the procedure was repeated. 
In the mBMC group, 20 (87%) patients experienced chest pain during cell injections 
under balloon inflation, and 16 (70%) had ischemic ST-segment changes on the ECG 
defined as  1 mm ST-segment depression or elevation at the J-point + 60 ms. There were 
no reinfarctions after cell injections as assessed by new elevation of CK-MB mass. All 
patients were alive, and the adverse event rate was generally low and not different in the 
groups.
Paper II 
This paper presents the main results of the ASTAMI study. A total of 101 patients were 
included in the study, one patient was excluded owing to early heart transplantation, and 
there were 50 patients in both the mBMC and the control group. For varying reasons, 3 
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patients in the mBMC  group did not receive mBMC injections. There were no 
differences between groups in patients baseline characteristics, with a mean age of 57±9 
years, a median time from symptom onset to PCI of 210 minutes (interquartile range 180 
to 330) and a median value for maximum CK-MB mass of 369 ȝg/L (interquartile range 
220 to 444). After 6 months follow-up, there was a similar improvement in global LV 
function in both groups. With the use of SPECT, LVEF increased with 8.1±11.2% in the 
mBMC group and with 7.0±9.6% in the control group (P=0.77 for difference between 
groups). With the use of echocardiography, LVEF increased with 3.1±7.9% in the 
mBMC group and with 2.1±9.2% in the control group (P=0.70). With the use of MRI, 
LVEF increased with 1.2±7.5% in the mBMC group and with 4.3±7.1% in the control 
group (P=0.054). The change in LVEF was not correlated to the number of injected 
mBMC. There were no differences between groups for the change in LVEDV and infarct 
size. All patients were alive, the rate of adverse events was generally low and not 
different between the groups. 
Paper III 
This paper presents results of exercise testing and quality of life assessment. There was a 
significantly greater improvement in exercise time in the mBMC group than in the 
control group (2.1±1.9 min in the mBMC group compared with 1.2±1.3 min in the 
control group (P<0.01)). Peak heart rate improved with 18.5±16.3 beats/min in the 
mBMC group compared with 13.3±15.8 beats/min (P<0.05). However, the improvement 
in peak VO2 was not different between the groups (2.8±3.9 ml/kg/min in the mBMC 
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group compared with 2.4±3.5 ml/kg/min in the control group, P=0.62), and the 
improvement in exercise time in the mBMC group compared with the control group is 
probably a placebo effect. There were no differences between groups for quality of life 
assessed by the SF-36 health survey, neither at baseline nor for the change from 2-3 
weeks to 6 months. The physical component summary (PCS) score improved 
significantly in both groups, whereas the mental component summary (MCS) score was 
mainly unchanged. At 6 months, both the PCS scores and the MCS scores were 
approximately at the same level as the general Norwegian population. 
Paper IV 
This paper summarizes changes in LV function over time, clinical outcome and safety 
during 12 months follow-up. Results obtained by echocardiography at baseline and at 3, 6 
and 12 months are presented, and there were no differences between groups for the 
changes in LVEF, WMSI or LVEDV. There was a similar improvement in LVEF and 
WMSI in both groups at 3 months followed by a stable state. For the entire patient 
population, LVEDV significantly increased at 6 months, but was unchanged compared to 
baseline at 3 and 12 months. The numbers of adverse events were similar in both groups, 
and all patients were alive after 12 months follow-up. 
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DISCUSSION 
In the randomized, but open-labeled ASTAMI study, intracoronary injection of 
autologous mBMC 4-8 days after anterior AMI did not improve LV function, quality of 
life, or infarct size. There was no difference between groups for the change in peak VO2,
and the significantly greater increase in exercise time in the mBMC group than in the 
control group was regarded to be a placebo-effect. We did not find a dose-response effect 
for the number of mBMC (or CD34+ cells, unpublished data). Our results indicate that 
mBMC treatment is safe, since all patients were alive after 12 months, and the numbers 
of adverse events were generally low and similar in the groups. 
Why were we unable to demonstrate a positive impact of cell therapy? 
Methodological considerations 
General
A phase III study to assess the effect of an intervention on the ultimate end point all-
cause mortality is usually regarded the gold-standard for cardiovascular trials. However, 
even though ischemic heart disease is a major cause of death world-wide and the major 
cause of congestive heart failure45, mortality rates are currently low in AMI patients 
treated with acute PCI. At RUH, 30 days mortality for all patients admitted with STEMI 
is 5.5%46. In clinical trials, high risk patients with e.g. advanced age or cardiogenic shock 
are typically not included, and mortality rates are low. Thus, thousands of patients would 
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have to be included to identify increased survival by any intervention. At the level of 
knowledge in this field at the time when the ASTAMI study was initiated, a phase III 
study would have been unethical. Therefore, the ASTAMI study was a phase II study. 
That means that in addition to confirming that intracoronary injection of autologous 
mBMC in patients with AMI was safe and feasible, the ASTAMI study was designed to 
evaluate the efficacy of this therapy. Treatment effect in a phase II trial is usually 
assessed with intermediate end points like measures of function and quality of life, or by 
a surrogate end point. The FDA defines a surrogate end point as a laboratory 
measurement or physical sign that is used in therapeutic trials as a substitute for a 
clinically meaningful end point that is a direct measure of how a patient feels, functions, 
or survives and is expected to predict the effect of the therapy. Especially patients with 
large, transmural infarcts are at particular risk of remodeling and the subsequent 
development of congestive heart failure (CHF) which again is associated with reduced 
survival5, 6. Therefore, improvement of LV function after AMI, which was the primary 
aim of the ASTAMI study, is a clinically relevant problem. Since BMC therapy was 
shown to regenerate myocardium and improve myocardial function in experimental 
models of AMI, attempts to improve LV function by BMC therapy in STEMI patients 
made intuitive sense and therefore has “face validity”. 
Variables of LV function that have been shown to predict outcome after AMI include 
LVEF47, 48, WMSI48, LV volumes49, infarct size50 and echocardiographic measures of 
diastolic function like the ratio of E/Ea51.  LVEF is a measure of LV global function, and 
as all end points, LVEF has limitations. LVEF is often well preserved after AMI because 
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of hyper-contractility of non-infarcted segments52, and may not be sensitive to detect 
changes in LV function. Furthermore, improvement in LVEF by an intervention does not 
necessarily translate to improved outcome53. However, LVEF is probably the best 
validated surrogate end point in cardiovascular trials. Improvement in LVEF and 
improved survival in patients with AMI has been shown for acute PCI54, 55, ACE 
inhibitors56, 57 and beta-blockers58, 59. Importantly, the degree of improvement in LVEF 
after vasodilator therapy (including ACE-inhibitors) predicted the clinical benefit60,
indicating a close connection between the surrogate and the clinical outcome. Therefore, 
the choice of LVEF as the primary end point in the ASTAMI study is probably an 
adequate measure of improved LV function and therefore has “construct validity”. 
Internal validity 
A study should be able to measure what it sets out to measure, i.e. it should have high 
internal validity. Bias may be defined as “deviation from truth”, and bias reduces the 
internal validity of a study. There are several forms of bias in research 
Selection bias 
This means that there is a systematic difference between the study groups. The aim of the 
randomization procedure is to avoid selection bias. In the ASTAMI study, selection bias 
was probably not widespread since we did not find any differences between groups at 
baseline, and no patients were lost to follow-up43.
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Information bias 
This means that there is a systematic difference between groups for collection of 
information. The ASTAMI study had potential for significant information bias since it 
was open-labeled (no sham procedures), and patients and some of the investigators were 
aware of treatment allocation. In other studies, the sham procedure has consisted of bone 
marrow aspiration and intracoronary injection of varying placebo mediums61, 62. These 
procedures are however not indifferent since both bone marrow aspiration63 and PCI 64
can induce an inflammatory response,  and repeated balloon inflations in the infarct 
related coronary artery can affect the infarct process65. Therefore, a sham procedure may 
in fact increase the possibility for information bias when comparing intracoronary BMC 
treatment to standard optimal therapy in AMI patients. To reduce the risk of information 
bias in the ASTAMI study, all analyses on laboratory measures like LV function and 
QCA were performed in a blinded fashion. The collection of data on quality of life and 
some variables of exercise capacity were subject to information bias (placebo effect) 
which would be believed to favor the treatment group. This is probably the explanation 
for the discrepancy on exercise capacity results, since patient motivation has greater 
impact on exercise time than peak VO2. Of the 50 patients randomized to cell therapy, 3 
patients did not receive mBMC treatment. Possible selection bias was avoided by the 
consistent use of the intention to treat strategy. This may have diluted a possible 
treatment effect of mBMC therapy, but this is probably not the case since exclusion of 
these 3 patients in the analyses did not influence results to a significant degree 
(unpublished data). 
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Repeatability and effect measure 
The validity of results depend on the repeatability of the effect measure. The greatest 
variability in assessment of LV function is usually caused by interrecording, followed by 
interobserver and then intraobserver variability66. Since the same investigator analyzed 
recordings for the same patient by SPECT and echocardiography, intraobserver and not 
interobserver variability was assessed. By MRI, interobserver variability is reported 
because this is of greater importance than intraobserver since different investigators 
analyzed recordings for the same patient. Re-read variability for LVEF by SPECT was 
-1.0±3.7%, and well within the estimated variation which was used for calculation of 
sample size (SD=8.3%). Variability was at the same level by echo, better by trueFISP 
MRI and worse when FLASH MRI was used. For practical reasons, we did not assess 
interrecording variability. However, De Winter et al examined 20 patients with coronary 
artery disease and LVEF below 40%67, and found day-to-day variability for LVEF by 
SPECT to be only 0.85±3.0%. Interrecording repeatability for SPECT (and the other 
imaging modalities) in ASTAMI was likely below this level. However, precision was 
probably well within the value used in the power calculations. 
Ideally, methods to assess the effect measure should also be accurate (reflect the truth). In 
ASTAMI, 3 inherent imaging techniques were used to measure LV function. Different 
values for LV volumes and infarct size were obtained with the different techniques, and 
this relates to methodological differences. At present, MRI with multiple short-axis 
recordings is regarded the gold standard for assessment of LV volumes. The 2D methods 
which were used to obtain LV volumes both for MRI and for echocardiography in 
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ASTAMI are based on theoretical assumptions on LV shape. Especially in AMI patients 
with regional wall motion abnormalities this may not be correct. Furthermore, 
repeatability for FLASH MRI which was used in the majority of patients was suboptimal, 
and a method with high variability is by definition not precise and is unlikely to be 
accurate68. The 3D approach which was used by SPECT is probably preferential, but it is 
unknown which method that best resembles true LV volumes (accuracy). However, the 
aim of the ASTAMI study was to assess differences between groups, not the absolute 
values per se. 
To conclude, results on the effect measure in ASTAMI were consistent, since none of the 
3 different imaging modalities revealed differences between groups for the change in 
LVEF, WMSI, LVEDV nor infarct size. This was also the case for quality of life data as 
well as exercise testing results, since objective measures like peak VO2, the anaerobic 
threshold (AT), time to AT, heart rate recovery, the VE/VCO2 slope and the oxygen 
uptake efficiency slope were also similar in the groups. This agreement is undoubtedly a 
strength of the ASTAMI study. 
Statistical bias 
This means the use of inappropriate statistical methods. In the ASTAMI study, analysis 
of covariance (ANCOVA) was used to assess end points with baseline and follow-up 
measurements (Paper II, III and IV). ANCOVA adjusts for possible baseline differences 
and is regarded more powerful than alternative methods like t-tests of follow-up or 
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change scores69. The general linear regression model used for repeated measures also 
adjusted for possible baseline differences (Paper IV)70. The main statistical limitation of 
the ASTAMI study is the relatively low power of 80%. This means that the probability of 
a type II error, i.e. that we did not detect a significant treatment effect when this was 
actually the case, was 20%. Another aspect is that a difference between groups of 5% for 
ǻ LVEF was considered a clinically important treatment effect of mBMC therapy. Even 
though this estimate is supported by data from the V-HeFT trials60, it is not known 
whether this is relevant for cell therapy, and less pronounced differences may potentially 
also be of importance. More patients would have to be included to detect a less 
pronounced treatment effect and/or to reduce the risk of a type II error. 
External validity 
During the inclusion period, we screened 1608 STEMI patients admitted for acute PCI 
for inclusion in the ASTAMI study43, and only 100 (6.2%) were included in the analysis. 
To what degree can results of the ASTAMI study be extended to the general AMI 
population? Acute PCI is currently the standard revascularization strategy for AMI 
patients in Norway, and even though the use of medical therapy in the ASTAMI study 
was extensive, this is also the case after AMI in the general Norwegian population71.
Table 1 shows differences between included and non-included patients for some variables 
that were collected during inclusion. Data are complete for RUH, but partially missing for 
UUH.
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Table 1 
Characteristics of included versus non-included patients 
Included Non-included P value 
Age 57.4±9.1
n=100
62.4±13.0
n=1502
<0.001
Female sex 16 (16%) 
n=100
360 (24%) 
n=1503
0.06
Caucasian etnicity 96 (96%) 
n=100
1421 (95%) 
n=1500
0.83
Maximum CK-MB  
(ȝg/L)
324 (190 to 400) 
n=60
225 (87 to 400) 
n=678
<0.01
Time from symptom 
onset to PCI 
210 (180 to 330) 
n=85
240 (170 to 420) 
n=1170
0.21
Data are mean±SD, number (proportion) or median (interquartile range). P values were obtained by the 
independent t-test, the chi-square test or the Mann-Whitney test as appropriate. For CK-MB, only data from 
RUH are presented since no data for non-included patients were available from UUH.  
Included patients were younger than non-included, and there was a strong trend for less 
women among included patients. When comparing only patients within the age inclusion 
criteria in ASTAMI (40 to 75 years), the age of non-included patients was 58.9±9.3 years 
(P = 0.14 compared with included patients), and there were 224 (19%) females in the 
non-included group (P = 0.39). Included patients had higher values for CK-MB, 
indicating that the inclusion criteria succeeded in selecting patients with large infarcts, 
where a positive treatment effect would have the greatest impact. The results of the 
ASTAMI study are therefore probably valid for patients of age 40 – 75 years with large 
infarcts. 
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Comparison with other studies 
Since the BMC subpopulation that may be responsible cardiac regeneration has not yet 
been identified, unfractioned BMC were used in the ASTAMI study and in several other 
trials. Results of the ASTAMI study have been said to be in conflict with similar studies, 
especially in relation to results of the REPAIR-AMI study62. In the REPAIR-AMI study, 
204 AMI patients reperfused with acute PCI were randomized to intracoronary injection 
of mBMC or placebo. The primary end point was the change in LVEF measured by 
single-plane angiocardiography. After 4 months follow-up, LVEF increased with 
5.5±7.3% in the mBMC group compared to 3.0±6.5% in the placebo group (p=0.01), i.e. 
an absolute treatment effect of 2.5% points. It has been suggested that different protocols 
for preparation of the bone marrow account for the different results, since mBMC 
prepared according to the ASTAMI protocol were found to have impaired functional 
capacity72. Especially the use of autologous heparin-plasma for overnight mBMC storage 
was found to reduce migratory capacity against SDF-1 in vitro, and neovascularisation 
capacity in a hind-limb ischemia model in mice, when compared to results obtained after 
storage in the cell culture medium X VIVO 10 (Cambrex Bio Science, Walkersville, MD, 
USA). Unfortunately, these experiments were performed by the REPAIR-AMI 
investigators only, based on an incomplete brief protocol version. It is therefore unknown 
whether the exact cell preparation conditions in the ASTAMI study were actually 
reproduced. Cell preparation in the ASTAMI study was based on methods that are proven 
to be successful for patients with hematological diseases40. Whether or not these results 
can be transferred to the clinical scenario of cardiac repair by BMC remains unknown. 
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Some preclinical data indicate that for reconstitution of the bone marrow, single cell 
grafting may be sufficient29, and mechanisms for homing and engraftment of BMC may 
be different in different organs. As discussed in the methods section, the cell culture 
medium RPMI-1640 was intended for cell storage in the original protocol, but for safety 
concerns, the use was restricted by the NoMA. In this respect, it is noteworthy that the 
manufacturer of X VIVO 10 is unaware of safety data for intracoronary administration of 
this substance73. The possibility that the use of RPMI-1640 would have changed the 
results of the ASTAMI study remains speculative. Instead, the simple fact that the 
ASTAMI study was not powered to detect a treatment effect of the change in LVEF of 
less than 5%, and the use of a suboptimal method for assessment of LV function in 
REPAIR-AMI73 may account for the different results. Table 2 summarizes results of 
larger randomized clinical trials with BMC therapy in patients with AMI. The change in 
LVEF was the primary end-point in most of these studies. In the BOOST trial, only a 
temporary treatment effect on LVEF was found74, 75, and results of the study by Janssens 
et al indicated reduced infarct size and improved regional function, but no effect on 
LVEF61. In a study with only 20 patients in each group, Meluzin et al found a small effect 
of 100x106 mBMC compared to 10x106 or control76, and in the rather small TCT-STAMI 
study, mBMC therapy improved LVEF compared to a control group where no 
improvement in LVEF was observed77. To conclude, the effect of BMC therapy in larger 
randomized clinical trials has at best been found moderate, and are therefore not in true 
conflict with results of the ASTAMI study. 
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General aspects 
The concept of intracoronary injection of BMC for improvement of LV function in 
patients with AMI has several limitations which may explain why we did not find a 
treatment effect in the ASTAMI study. 
Transdifferentiation 
Several groups could not reproduce transdifferentiation of BMC, and fusion of 
transplanted cells with host-cells may have accounted for the observations that were 
interpreted as transdifferentiation78, 79. Another possible explanations for the discrepancy 
include different techniques for detection of transplanted cells80. Orlic et al at the 
Valhalla institute injected BMC tagged with green fluorescent protein, and trusted the 
identification of fluorescent cardiomyocytes as an indication of transdifferention of BMC 
to cardiomyocytes22. These findings may however have been mixed with cardiomyocyte 
autofluorescence artefacts81. When more sophisticated genetic markers were used, either 
little activity of the reporter was observed82, or BMC were shown to differentiate to 
mature blood cells when placed in ischemic myocardium83. Recently, in a cooperation 
with three other laboratories, the researchers at the Valhalla institute provided repeated 
evidence that BMC actually can transdifferentiate and regenerate myocardium84.
Unfortunately, none of the laboratories behind the negative transdifferentiation reports 
participated in the new studies. Whether significant myocardial regeneration by 
transdifferentiation of BMC is possible or not remains unsettled. 
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The initial findings of large amounts (9% with 50% sensitivity, indicating a total of 18%) 
of recipient derived cardiomyocytes in sex-mismatched heart transplantation32 have also 
been challenged. Other investigators found only 0.02-0.04% cardiomyocytes with 
recipient origin in the transplanted hearts85, 86. Thus, the biological significance of 
possible cardiac repair by BMC as a naturally occurring phenomenon has been 
questioned.
Even though the original concept of transdifferentiation to cardiomyocytes is heavily 
disputed, BMC have improved myocardial function in most studies after experimental 
myocardial infarction. However, similar results have been obtained by transplantation of 
numerous cell types including skeletal myoblasts87, smooth muscle cells88, and 
fibroblasts89. Thus, it seems like every cell type exert a positive effect after 
intramyocardial injection90. This may in part be explained by improved passive 
mechanical properties of the myocardium purely after injection of material like cellular 
masses91. Furthermore, since it is unlikely that so many cell types have potential for 
transdifferentiation to cardiomyocytes, other explanations for possible mechanism have 
been suggested. The concept that bone-marrow derived EPC contribute to formation of 
new blood vessels (angiogenesis) is less controversial92. Indeed, in an early report in 
2001, Kocher et al found that transplanted human EPC indirectly reduced cardiomyocyte 
apoptosis after experimental AMI in mice through angiogenesis 37. Thus, improved 
perfusion may be the mechanism behind the improvement in LV function that have been 
observed after mBMC treatment62, and a phase I study with EPC for treatment of patients 
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with severe angina pectoris and no further revascularization options have yielded positive 
results93.
Other mechanisms 
BMC secrete growth factors and cytokines that are known to exert angiogenic effects, 
and may stimulate endogenous cardiac repair by paracrine action rather than 
transdifferentiation to cardiac cells94. For example, similar reduction of infarct size and 
improvement of myocardial function was found either MSC or only the cell-free 
conditioned media was injected after experimental AMI95. Immune modulation is another 
suggested mechanism96, and indeed, mBMC therapy may have resulted in a slightly 
reduced long-term inflammatory response in the ASTAMI study97. However, cell therapy 
strategies that may work in otherwise young and healthy laboratory animals, may not 
have the same potential in a clinical setting with older patients with multiple risk factors, 
where both cell functionality and the biological responses to cell therapy are likely to be 
impaired98.
Dose
The left ventricle contains approximately 4-5 x 109 cardiomyocytes90, 99. In the ASTAMI 
study, the mean infarct size at 6 months was approximately 20% by MRI and 30% by 
SPECT. Thus, at least 1 x 109 cardiomyocytes should ideally be replaced. The median 
number of mBMC injected in the ASTAMI study was 68x106, the median number of 
CD34+ progenitor cells was 0.7x106, and the number of MSC and multipotent HSC was 
even smaller since these cells are scarce within the bone marrow. Furthermore, only a 
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few % of the cells remain in the heart after intracoronary injection100, 101, and a large 
proportion die within a few days102. Accordingly, the number of cells that were delivered 
were out of proportion compared to the need. Cell numbers in the ASTAMI study was 
higher than in the study by Strauer et al38 and the TCT-STAMI study77, similar to the 
study by Fernandez-Aviles et al103 and the high dose group in the study by Meluzin et
al76, and less than in the BOOST study74, the study by Janssens et al61 and the REPAIR-
AMI study62. However, a large discrepancy between the number of cardiomyocytes that 
need to be regenerated after an AMI and the number of stem and progenitor cells that 
have been transplanted to the heart is a common feature of all the studies that have been 
performed. Relative to the size of the heart, more cells were transplanted in the studies in 
mice. Assuming mouse and human BMC to be equally efficacious, and considering 
transdifferentiation possible, it has been calculated that at best 1-5 g myocardium could 
be regenerated in the human trials with the number of transplanted cells104. Another issue 
questioning the concept is the lack of a dose-response relationship in the clinical studies. 
In the TOPCARE-AMI105, the BOOST study74, and the ASTAMI study43, no significant 
correlation between improvement in LV function and the total number of BMC or 
CD34+ cells was found. This may however be related to underdosing in all the studies. If 
regeneration of myocardium was limited to 5 g, it is unlikely that any available method 
for assessment of LV function could have detected a treatment effeect104.
Cell delivery 
Intracoronary injection of BMC is a relatively simple and feasible technique for delivery 
of cells to the human heart. The technique was first described by Strauer et al, and it was 
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based on the assumption that BMC would be attracted by cytokines and signalling 
molecules, adhere to the endothelium at the sites of myocardial necrosis by expression of 
specific receptors, extravasate and engraft in niches in the myocardium (homing)38. By 
this method, cells are delivered to perfused areas of the myocardium, reducing the risk of 
ischemic cell death.  Studies have however shown that 1-2 hours after administration of 
cells, only 1-5% of radiolabeled BMC remain in the heart by this method100, 101. Hofmann 
et al showed superior retention of CD34+ progenitor cells (14-39% remained in the heart 
60-75 min after intracoronary injection)100. This was however not confirmed by Blocklet 
et al, who found only 5.5% of CD34+ cells within the myocardium 1 hour after 
injection106.  Therefore, it seems obligate to improve methods for cell delivery to obtain a 
treatment effect. However, cell engraftment by alternative methods for cell delivery is 
also disappointing. In a porcine model of AMI, Hou et al tested the efficacy of 
intracoronary, retrograde coronary venous injection and direct intramyocardial injections 
of peripheral blood mononuclear cells107. One hour after cell delivery, 11% of the cells 
remained in the heart after intramyocardial injections, whereas only approximately 3% of 
the cells remained in the heart by the other methods. Therefore, further research to 
increase engraftment of transplanted cells within the myocardium seems mandatory to 
improve results after cell therapy, irrespective of whether transdifferentiation, paracrine 
effects or immune-modulation are involved. 
Timing of treatment 
Strauer et al estimated the ideal timing for cell delivery to be between 7 and 14 days after 
the AMI, based on the assumption that earlier treatment would expose the cells to a 
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hostile, inflammatory environment, and that effects of later treatment would be hampered 
by scar formation within the myocardium38. In the TOPCARE-AMI study, cells were 
delivered 4±1.5 days after the AMI39. In the ASTAMI study, timing of treatment to day 
4-8 after the AMI was also based on assumptions of a trade-off between the early 
inflammatory response, and the subsequent scar development. Results of the REPAIR-
AMI study showed that the improvement in LV function was confined to the patients 
which were treated 5 days after the AMI62. However, we did not observe any treatment 
effect even though cells were injected at a median of 6 days after the AMI43. In a small 
study, beneficial effects of intracoronary mBMC injections were found when cells were 
injected in the hyperacute phase of the AMI, i.e. a mean time of 3 hours after PCI77. Few 
experimental studies have assessed the effect of timing on engraftment and efficacy of 
cell therapy108. However, neither timing nor cell type (MSC or mBMC) affected 
engraftment after intramyocardial injections in experimental infarction in rats109.
Currently, the ideal timing for cell delivery after AMI is unknown. 
PERSPECTIVES
Cell therapy for heart disease is in its infancy. Further research is needed to identify the 
optimal cell type and dose, improve cell delivery techniques and to determine the optimal 
timing for cell treatment. Specific BMC subpopulations may be preferential compared to 
unfractioned BMC, and Chen et al reported a large treatment effect of intracoronary 
injection of MSC110, but these results need to be confirmed in other studies. The safety of 
MSC have been questioned, since intracoronary injection of such cells caused 
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microinfarction in dogs111, and recently, myocardial ossification was observed after 
intramyocardial injections of MSC in mice112. EPC seem to be a reasonable cell type for 
therapeutic angiogenesis, and results of phase II studies with intramyocardial injections 
of such cells in patients with angina pectoris and no further revascularisation 
opportunities are awaited. Mobilisation of BMC with the cytokine granulocyte colony-
stimulating factor (G-CSF) has been tested clinically as an alternative to the direct 
cardiac administration of BMC. Data from clinical trials indicate that administration of 
G-CSF presently has no role for treatment of patients with ischemic heart disease113.
Intramyocardial injection of skeletal myoblasts has been tested in patients with 
established myocardial scars. These cells are however committed to become skeletal 
myocytes and do not integrate with the myocardium since they do not express gap 
junction proteins. In the largest study testing this approach to date, results were rather 
disappointing114.
Without doubt, ESC have potential for differentiation to all cell types needed for 
myocardial regeneration. The use of ESC is however hampered by several concerns. The 
ethical aspect is controversial, the rate of spontaneous cardiomyocyte differentiation of 
ESC is low and cell survival is poor after transplantation of undifferentiated ESC115 or 
unmanipulated human ESC derived cardiomycytes116 to the heart. The pluripotency of 
these cells is also a safety concern, since teratomas were observed after intramyocardial 
injection of undifferentiated ESC115, 117. Several of these hurdles may be overcome, and 
techniques for increased cardiomyocyte differentiation and survival of human ESC after 
transplantation to infarcted rat hearts have been described115, 116. Some researchers 
believe ESC are immune privileged, since they express low levels of major 
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histocompatibility complex (MHC) molecules and insignificant recognition by natural 
killer receptors118. However, exposure to inflammation (interferon-Ȗ) increased 
expression of MHC molecules118, and after intramyocardial injection of ESC in infarcted 
baboon hearts, all transplanted cells were rejected119. Somatic cell nuclear transfer was 
suggested as a novel technique to produce immune privileged human ESC, but this 
opportunity remains hypothetical since these reports were found to be manipulated120.
ESC transplantation appears less attractive if close MHC matching and 
immunosuppresion is needed to avoid rejection of transplanted cells. Recently, the 
findings that human skin fibroblasts can be genetically modified to obtain pluripotent 
stem cells121, 122 has created great expectations for the future of regenerative medicine.  It 
is however currently unknown whether such cells can be used to regenerate the heart. 
CONCLUSION 
In the ASTAMI study, we did not find any clinically significant effects of intracoronary 
injection of autologous mBMC in patients with AMI. The lack of a treatment effect may 
be a type II error, and possibly, alternative methods for preparing mBMC may have 
changed results. However, our results are not in true conflict with results of other, similar 
studies. The restricted clinical success is probably related to conceptual limitations like 
insufficient cell numbers permanently engrafted in the myocardium, and the questionable 
capacity for transdifferentiation of BMC to cardiomyocytes. Further research is needed 
before cell treatment can be recommended for patients with AMI. 
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